Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma-Reference-Cited by-同舟云学术

Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma

Published:2001-03 Issue:5 Volume:37 Page:597-604
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Twelves C,Boyer M,Findlay M,Cassidy J,Weitzel C,Barker C,Osterwalder B,Jamieson C,Hieke K

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Global cancer statistics;Parkin;CA Cancer J. Clin.,1999

2. Cancer statistics 1999;Landis;CA Cancer J. Clin.,1999

3. Colorectal cancer;Midgley;Lancet,1999

4. Williams NS, Northover JMA, Arnott SJ, Jass JR. Colorectal tumours. In Oxford Textbook of Oncology 1995, 1133–1168.

5. Worldwide patterns of cancer mortality, 1985–89;Levi;Eur. J. Cancer Prev.,1994

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TGF-β in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer;Medical Oncology;2023-10-19

2. 5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review);Oncology Reports;2023-08-07

3. Provider responses to the expansion of public subsidies in healthcare: The case of oral chemotherapy treatment in Australia;Social Science & Medicine;2023-08

4. Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: A nationwide cohort study;Radiotherapy and Oncology;2023-06

5. Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors;Current Problems in Cancer;2023-02